<SEC-DOCUMENT>0001654954-24-005107.txt : 20240429
<SEC-HEADER>0001654954-24-005107.hdr.sgml : 20240429
<ACCEPTANCE-DATETIME>20240429071811
ACCESSION NUMBER:		0001654954-24-005107
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240429
FILED AS OF DATE:		20240429
DATE AS OF CHANGE:		20240429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASTRAZENECA PLC
		CENTRAL INDEX KEY:			0000901832
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11960
		FILM NUMBER:		24886585

	BUSINESS ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA
		BUSINESS PHONE:		011 44 20 7304 5000

	MAIL ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZENECA GROUP PLC
		DATE OF NAME CHANGE:	19930422
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>astrazenecaplc3089m.htm
<DESCRIPTION>TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2024 Issuer Direct Corporation -->
<title>astrazenecaplc3089m</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM 6-K</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">SECURITIES
AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Washington,
D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Report
of Foreign Issuer</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to Rule 13a-16 or 15d-16 of</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">the
Securities Exchange Act of 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For the
month of April 2024</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Commission
File Number: 001-11960</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1
Francis Crick Avenue</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Cambridge
Biomedical Campus</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Cambridge
CB2 0AA</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">United
Kingdom</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Form
20-F X Form 40-F __</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Yes __
No X</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If
&#x201C;Yes&#x201D; is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">INDEX
TO EXHIBITS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
1.</font> <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Truqap recommended for EU breast cancer approval</font>
<div style="display: table-row"></div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
29 April 2024</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; font-style: italic; color: #000000; font-size: 13px; background-color: #FFFFFF">
Truqap</font><font style="color: #000000">&#xA0;</font><font style="font-weight: bold; color: #000000; font-size: 13px; background-color: #FFFFFF">plus</font><font style="font-weight: bold; color: #000000; font-size: 13px; background-color: #FFFFFF">&#xA0;</font><font style="font-weight: bold; font-style: italic; color: #000000; font-size: 13px; background-color: #FFFFFF">Faslodex</font><font style="color: #000000">&#xA0;</font><font style="font-weight: bold; color: #000000; font-size: 13px">recommended
for approval in the EU by CHMP for</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<font style="color: #000000">patients with advanced ER-positive
bre</font><font style="color: #000000; background-color: #FFFFFF">ast
cancer</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Recommendation based on CAPItello-291 results which showed the
Truqap combination reduced the risk of disease</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
progression or death by 50%</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
vs. Faslodex standard of care in a biomarker-altered
population</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">
AstraZeneca</font><font style="color: #000000; font-size: 13px">'s</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px; background-color: #FFFFFF">Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">(capivasertib)
in combination with</font><font style="color: #000000; background-color: #FFFFFF">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px; background-color: #FFFFFF">Faslodex</font><font style="color: #000000; background-color: #FFFFFF">&#xA0;</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">(fulvestrant)</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">has
been recommended</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">for
approval in the European Union (EU) for the
treatment</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">of
adult patients with estrogen receptor (ER)-positive, HER2-negative
locally advanced or metastatic breast cancer with one or more
PIK3CA, AKT1, or PTEN-alterations</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">following
recurrence or progression on or after an endocrine-based
regimen.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
The Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) based its positive opinion
on</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">the
results from the</font><font style="color: #000000">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px; background-color: #FFFFFF">CAPItello-291</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">Phase
III trial</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">published
in&#xA0;</font><font style="font-style: italic; text-decoration: underline; color: #0000FF; font-size: 13px">The
New England Journal of Medicine</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">
In the trial,</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px; background-color: #FFFFFF">Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">in
combination with</font><font style="color: #000000; background-color: #FFFFFF">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px; background-color: #FFFFFF">Faslodex</font><font style="color: #000000; background-color: #FFFFFF">&#xA0;</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">reduced
the risk of disease progression or death by 50%
versus</font><font style="color: #000000; background-color: #FFFFFF">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px; background-color: #FFFFFF">Faslodex</font><font style="color: #000000; background-color: #FFFFFF">&#xA0;</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">alone
in patients with tumours harbouring PI3K, AKT or PTEN
alterations</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">(based on hazard ratio of 0.50,
95% confidence interval 0.38-0.65; p=&lt;0.001; median
progression-free survival (PFS) 7.3 versus 3.1
months).</font><font style="font-size: 70%; vertical-align: top; color: #000000">1</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 9.1px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
In Europe, breast cancer remains the leading cause of cancer death,
with more than 140,000 deaths in 2022 and more than 550,000 new
patients diagnosed in the same year.</font><font style="font-size: 70%; vertical-align: top; color: #000000">2</font><font style="color: #000000; font-size: 13px">&#xA0;HR-positive
breast cancer</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">(expressing
estrogen</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">or progesterone receptors, or
both),</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">is the most common subtype of
breast cancer with 70% of tumours considered HR-positive and
HER2-low or HER2-negative.</font><font style="font-size: 70%; vertical-align: top; color: #000000; background-color: #FFFFFF">3</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">More
than 97%</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">of HR-positive breast cancer
tumours are ER-positive.</font><font style="font-size: 70%; vertical-align: top; color: #000000">4,5</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px; background-color: #FFFFFF">Collectively,
mutations in PIK3CA, AKT1 and alterations in PTEN occur frequently,
affecting approximately 50% of patients with advanced HR-positive
breast cancer.</font><font style="font-size: 70%; vertical-align: top; color: #000000; background-color: #FFFFFF">6</font><font style="font-size: 70%; vertical-align: top; color: #000000">-8</font><font style="color: #000000; font-size: 13px">&#xA0;HR-positive
breast cancer progression is often driven by estrogen receptors,
and endocrine therapies that target ER-driven disease are widely
used as 1st-line treatment in the advanced setting, and often
paired with CDK4/6 inhibitors.</font><font style="font-size: 70%; vertical-align: top; color: #000000">9-11</font><font style="color: #000000; font-size: 13px">&#xA0;However,
resistance to these therapies develops in many patients with
advanced disease, and alternative approaches are needed to extend
the effectiveness of endocrine-based therapies.</font><font style="font-size: 70%; vertical-align: top; color: #000000">10</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 9.1px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
Mafalda Oliveira, MD,</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">PhD, Senior Consultant at
the</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">Department of Medical Oncology,
Vall d'Hebron University Hospital, and Senior Clinical Investigator
of the Vall d'Hebron Institute of Oncology's (VHIO) Breast Cancer
Group in Barcelona, Spain, said: "There is an urgent need to extend
the effectiveness of widely used endocrine therapies in patients
with advanced ER-positive breast cancer to delay disease
progression or resistance.</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">With this combination
demonstrating a fifty per cent reduction in disease progression or
death in patients with tumours harbouring PIK3CA, AKT1, or
PTEN-alterations in the CAPItello-291 trial, this positive
recommendation marks an important step in providing a much-needed
new treatment option for approximately half of patients in this
setting with these specific tumour biomarkers."</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
Susan Galbraith, Executive Vice President, Oncology R&amp;D,
AstraZeneca, said: "Today's news reinforces the practice-changing
potential of</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">in
combination with</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Faslodex</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">to
extend the effectiveness of endocrine-based treatment approaches
for patients who experience tumour progression on, or resistance to
widely used endocrine-based therapies. This
recommendation</font><font style="color: #000000; font-family: Times New Roman; font-size: 16px">&#xA0;</font><font style="color: #000000; font-size: 13px">recognises
the high unmet need in this biomarker-specific patient population,
and if approved, patients in Europe</font><font style="color: #000000; font-family: Times New Roman; font-size: 16px">&#xA0;</font><font style="color: #000000; font-size: 13px">with
this specific type of disease</font><font style="color: #000000; font-family: Times New Roman; font-size: 16px">&#xA0;</font><font style="color: #000000; font-size: 13px">may
be able to benefit from this</font><font style="color: #000000; font-family: Times New Roman; font-size: 16px">&#xA0;</font><font style="color: #000000; font-size: 13px">first-in-class
treatment option."</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
In the CAPItello-291</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">trial, the safety profile
of</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">plus</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Faslodex</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">was
similar to that observed in previous trials evaluating this
combination.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
Regulatory applications are currently under review in China and
several other countries, and similar indications
for</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">in
combination with</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Faslodex</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">are
already approved in&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">Japan</font><font style="color: #000000; font-size: 13px">,
the&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">US</font><font style="color: #000000; font-size: 13px">&#xA0;and
several other countries based on results from the CAPItello-291
trial.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Notes</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
HR-positive breast cancer</font> <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
In Europe, breast cancer remains the leading cause of cancer death,
with more than 140,000 deaths in 2022 and more than 550,000 new
patients diagnosed in the same year.</font><font style="font-size: 70%; vertical-align: top; color: #000000">2</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 9.1px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
HR-positive breast cancer</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">(expressing
estrogen</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">or progesterone receptors, or
both),</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">is the most common subtype of
breast cancer with 70% of tumours considered HR-positive and
HER2-low or HER2-negative.</font><font style="font-size: 70%; vertical-align: top; color: #000000; background-color: #FFFFFF">3</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 9.1px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
HR-positive breast cancer progression is often driven by estrogen
receptors, and endocrine therapies that target ER-driven disease
are widely used as 1st-line treatment in the advanced setting, and
often paired with CDK4/6 inhibitors.</font><font style="font-size: 70%; vertical-align: top; color: #000000">9-11</font><font style="color: #000000; font-size: 13px">&#xA0;However,
resistance to CDK4/6 inhibitors and current endocrine therapies
develops in many patients with advanced disease.</font><font style="font-size: 70%; vertical-align: top; color: #000000; background-color: #FFFFFF">10</font><font style="color: #000000; font-size: 13px">&#xA0;Once
this occurs, treatment options are limited - with chemotherapy
being the current standard of care</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">-</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">and survival rates are low with
approximately 35% of patients anticipated to live beyond five years
after diagnosis.</font><font style="font-size: 70%; vertical-align: top; color: #000000; background-color: #FFFFFF">3,10,12</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 9.1px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
The optimisation of</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">endocrine therapy and overcoming
resistance to enable patients to continue benefiting from these
treatments, as well as identifying new therapies for those who are
less likely to benefit, are active areas of focus for breast cancer
research.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CAPItello-291</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
CAPItello-291 is a Phase III, double-blind, randomised trial
evaluating the efficacy of</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">in
combination with</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Faslodex</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">versus
placebo plus</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Faslodex</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">for
the treatment of locally advanced (inoperable) or metastatic
HR-positive (ER-positive and ER-positive, progesterone
receptor-positive), HER2-low or negative (immunohistochemistry
(IHC) 0 or 1+, or IHC 2+/in-situ hybridisation (ISH)-negative)
breast cancer.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The global trial enrolled 708 adult patients with histologically
confirmed HR-positive, HER2-low or negative breast cancer whose
disease has recurred or progressed during or after aromatase
inhibitor therapy, with or without a CDK4/6 inhibitor, and up to
one line of chemotherapy for advanced disease. The trial has dual
primary endpoints of PFS in the overall patient population and in a
population of patients whose tumours have qualifying alterations in
the PI3K/AKT pathway (PIK3CA, AKT1 or PTEN genes). In the trial,
approximately 40% of tumours had these alterations and
approximately 70% of patients received a prior CDK4/6
inhibitor.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Truqap</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000; font-size: 13px">
Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">is a first-in-class, potent,
adenosine triphosphate (ATP)-competitive inhibitor of all three AKT
isoforms (AKT1/2/3).</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">400mg
is administered twice daily according to an intermittent dosing
schedule of four days on and three days off. This was chosen in
early phase trials based on tolerability and the degree of target
inhibition.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000; font-size: 13px">
Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">is approved in Japan, the US and
several other countries for the treatment of adult patients with
HR-positive, HER2-negative locally advanced or metastatic breast
cancer with one or more biomarker alterations (PIK3CA, AKT1 or
PTEN) following recurrence or progression on or after an
endocrine-based regimen based on the results from the CAPItello-291
trial.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000; font-size: 13px">
Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">is currently being evaluated in
Phase III trials for the treatment of multiple subtypes of breast
cancer and in other tumour types in combination with established
treatments. The ongoing clinical research programme is focused on
tumours reliant on signalling via the PI3K/AKT pathway, and in
tumours harbouring biomarker alterations in this
pathway.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000; font-size: 13px">
Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">was discovered by AstraZeneca
subsequent to a collaboration with Astex Therapeutics (and its
collaboration with the Institute of Cancer Research and Cancer
Research Technology Limited).</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Faslodex</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000; font-size: 13px">
Faslodex</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">is an endocrine therapy indicated
for the treatment of estrogen receptor-positive, locally advanced
or metastatic breast cancer in postmenopausal women not previously
treated with endocrine therapy, or with disease relapse on or after
adjuvant anti-estrogen therapy, or disease progression on
anti-estrogen therapy.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
In the US, EU and Japan</font><font style="font-style: italic; color: #000000; font-size: 13px">,
Faslodex</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">is also approved in combination
with CDK4/6 inhibitors for the treatment of women with HR-positive,
HER2-negative advanced or metastatic breast cancer, whose cancer
has progressed after endocrine medicine</font><font style="font-style: italic; color: #000000; font-size: 13px">.
Faslodex</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">represents a hormonal treatment
approach that helps to slow tumour growth by blocking and degrading
the estrogen receptor - a key driver of disease
progression.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000; font-size: 13px">
Faslodex</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">is approved as monotherapy or in
combination with medicines from various drug classes including
CDK4/6, PI3K and AKT inhibitors for the treatment of patients with
HR-positive advanced breast cancer and is being evaluated in
combination with medicines from other drug
classes.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca in breast cancer</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Driven by a growing understanding of breast cancer biology,
AstraZeneca is starting to challenge, and redefine, the current
clinical paradigm for how breast cancer is classified and treated
to deliver even more effective treatments to patients in need -
with the bold ambition to one day eliminate breast cancer as a
cause of death.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca has a comprehensive portfolio of approved and promising
compounds in development that leverage different mechanisms of
action to address the biologically diverse breast cancer tumour
environment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
With</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Enhertu</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">(trastuzumab
deruxtecan), a HER2-directed antibody drug conjugate (ADC),
AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in
previously treated HER2-positive and HER2-low metastatic breast
cancer and are exploring its potential in earlier lines of
treatment and in new breast cancer settings.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
In HR-positive breast cancer, AstraZeneca continues to improve
outcomes with foundational medicines</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Faslodex</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">and</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Zoladex</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">(goserelin)
and aims to reshape the HR-positive space with first-in-class AKT
inhibitor,</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Truqap</font><font style="color: #000000; font-size: 13px">,
and next-generation SERD and potential new medicine camizestrant.
AstraZeneca is also collaborating with Daiichi Sankyo to explore
the potential of TROP2-directed ADC, datopotamab deruxtecan, in
this setting.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
PARP inhibitor</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Lynparza</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">(olaparib)
is a targeted treatment option that has been studied in early and
metastatic breast cancer patients with an inherited BRCA mutation.
AstraZeneca with MSD (Merck &amp; Co., Inc. in the US and Canada)
continue to research</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Lynparza</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">in
these settings and to explore its potential in earlier
disease.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
To bring much-needed treatment options to patients with
triple-negative breast cancer, an aggressive form of breast cancer,
AstraZeneca is evaluating the potential of datopotamab deruxtecan
alone and in combination with immunotherapy</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Imfinzi</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">(durvalumab),</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Truqap</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">in
combination with chemotherapy, and</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Imfinzi</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">in
combination with other oncology medicines,
including</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Lynparza</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">and</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Enhertu</font><font style="color: #000000; font-size: 13px">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca in oncology</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca is leading a revolution in oncology with the ambition
to provide cures for cancer in every form, following the science to
understand cancer and all its complexities to discover, develop and
deliver life-changing medicines to patients.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company's focus is on some of the most challenging cancers. It
is through persistent innovation that AstraZeneca has built one of
the most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal &amp; Metabolism, and Respiratory &amp;
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">astrazeneca.com</font><font style="color: #000000; font-size: 13px">&#xA0;and
follow the Company</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">on social
media</font><font style="color: #000000">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">@</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">AstraZeneca</font><font style="color: #000000; font-size: 13px">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Contacts</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
For details on how to contact the Investor Relations Team, please
click</font><font style="font-weight: bold; color: #000000; font-size: 13px">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">here</font><font style="color: #000000; font-size: 13px">.
For Media contacts, click&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">here</font><font style="color: #000000; font-size: 13px">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
References</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">1.&#xA0;&#xA0;</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Turner
N, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast
Cancer.</font><font style="color: #000000; font-size: 13px">&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">NEJM</font><font style="color: #000000; font-size: 13px">.
2023; 388:2058-70.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#x200B;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">2.&#xA0;&#xA0; World Health
Organization. GLOBOCAN Europe Fact Sheet. Available
at:</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://gco.iarc.who.int/media/globocan/factsheets/populations/908-europe-fact-sheet.pdf</font><font style="color: #000000; font-size: 13px">.
Accessed April 2024.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#x200B;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">3.&#xA0;&#xA0;</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">National
Cancer Institute. Surveillance, Epidemiology and End Results
Program. Available at:</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://seer.cancer.gov/statfacts/html/breast-subtypes.html</font><font style="color: #000000; font-size: 13px">.
Accessed April 2024.</font></font></div>
<div style="margin-left: 24px; margin-right: 0px; text-indent: -24px; color: #000000; letter-spacing: normal; white-space: normal; padding-top: 6px; padding-bottom: 6px"><font style="font-style: normal; font-weight: 400; font-size: medium; font-family: Times New Roman, Serif">
<font style="font-size: 13px; font-family: Times New Roman">4.
&#xA0;</font>&#xA0;<font style="font-size: 13px; font-family: Times New Roman"><font style="font-size: 13px; font-family: Times New Roman">Bae S, et al. Poor
prognosis of single hormone receptor positive breast cancer:
similar outcome as triple-negative breast
cancer.</font>&#xA0;<font style="font-style: italic; font-size: 13px; font-family: Times New Roman">BMC
Cancer</font><font style="font-size: 13px; font-family: Times New Roman">. 2015;
15:138.</font></font></font></div>
<div style="margin-left: 24px; margin-right: 0px; text-indent: -24px; color: #000000; letter-spacing: normal; white-space: normal; padding-top: 6px; padding-bottom: 6px"><font style="font-style: normal; font-weight: 400; font-size: medium; font-family: Times New Roman, Serif">
<font style="font-size: 13px; font-family: Times New Roman">5.
&#xA0;</font>&#xA0;<font style="font-size: 13px; font-family: Times New Roman"><font style="font-size: 13px; font-family: Times New Roman">Cserni G, et al.
Estrogen Receptor Negative and Progesterone Receptor Positive
Breast Carcinomas-How Frequent are they?</font>&#xA0;<font style="font-style: italic; font-size: 13px; font-family: Times New Roman">Pathol.
Oncol. Res.</font>&#xA0;<font style="font-size: 13px; font-family: Times New Roman">2011;
17:663-668.</font></font></font></div>
<div style="margin-left: 24px; margin-right: 0px; text-indent: -24px; color: #000000; letter-spacing: normal; white-space: normal; padding-top: 6px; padding-bottom: 6px"><font style="font-style: normal; font-weight: 400; font-size: medium; font-family: Times New Roman, Serif">
<font style="font-size: 13px; font-family: Times New Roman">6.&#xA0;&#xA0;</font>&#xA0;<font style="font-size: 13px; font-family: Times New Roman"><font style="font-size: 13px; font-family: Times New Roman">Howell
S J, et al. Fulvestrant plus capivasertib versus placebo after
relapse or progression on an aromatase inhibitor in metastatic,
oestrogen receptor-positive, HER2-negative breast cancer
(FAKTION).&#xA0;</font><font style="font-style: italic; font-size: 13px; font-family: Times New Roman">J
Clin Oncol.</font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;2022;
23:851-64.</font></font></font></div>
<div style="margin-left: 24px; margin-right: 0px; text-indent: -24px; color: #000000; letter-spacing: normal; white-space: normal; padding-top: 6px; padding-bottom: 6px"><font style="font-style: normal; font-weight: 400; font-size: medium; font-family: Times New Roman, Serif">
<font style="font-size: 13px; font-family: Times New Roman">7.&#xA0;&#xA0;</font>&#xA0;<font style="font-size: 13px; font-family: Times New Roman">Hortobagyi
G N, et al.</font>&#xA0;<font style="font-size: 13px; font-family: Times New Roman"><font style="font-size: 13px; font-family: Times New Roman">Correlative
Analysis of Genetic Alterations and Everolimus Benefit in Hormone
Receptor-Positive, Human Epidermal Growth Factor Receptor
2-Negative Advanced Breast Cancer: Results From
BOLERO-2.&#xA0;</font><font style="font-style: italic; font-size: 13px; font-family: Times New Roman">J
Clin Oncol.</font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;2016;
34:419-26.</font></font></font></div>
<div style="margin-left: 24px; margin-right: 0px; text-indent: -24px; color: #000000; letter-spacing: normal; white-space: normal; padding-top: 6px; padding-bottom: 6px"><font style="font-style: normal; font-weight: 400; font-size: medium; font-family: Times New Roman, Serif">
<font style="font-size: 13px; font-family: Times New Roman">8.&#xA0;&#xA0;</font>&#xA0;<font style="font-size: 13px; font-family: Times New Roman"><font style="font-size: 13px; font-family: Times New Roman">Millis
S Z, et al. Landscape of phosphatidylinositol-3-kinase pathway
alterations across 19784 diverse solid
tumors.&#xA0;</font><font style="font-style: italic; font-size: 13px; font-family: Times New Roman">JAMA
Oncol.</font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;2016;2(12):1565-73.</font></font></font></div>
<div style="margin-left: 24px; margin-right: 0px; text-indent: -24px; color: #000000; letter-spacing: normal; white-space: normal; padding-top: 6px; padding-bottom: 6px"><font style="font-style: normal; font-weight: 400; font-size: medium; font-family: Times New Roman, Serif">
<font style="font-size: 13px; font-family: Times New Roman">9.
&#xA0;</font>&#xA0;<font style="font-size: 13px; font-family: Times New Roman"><font style="font-size: 13px; font-family: Times New Roman">Lin M, et al.
Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine
Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive,
HER2-negative metastatic breast cancer.</font>&#xA0;<font style="font-style: italic; font-size: 13px; font-family: Times New Roman">J
Cancer</font><font style="font-size: 13px; font-family: Times New Roman">. 2020;
10.7150/jca.48944.</font></font></font></div>
<div style="margin-left: 24px; margin-right: 0px; text-indent: -24px; color: #000000; letter-spacing: normal; white-space: normal; padding-top: 6px; padding-bottom: 6px"><font style="font-style: normal; font-weight: 400; font-size: 13px; font-family: Times New Roman">
<font style="font-size: 13px; font-family: Times New Roman">10.&#xA0;</font>&#xA0;<font style="font-size: 13px; font-family: Times New Roman"><font style="font-size: 13px; font-family: Times New Roman">Lloyd
M R, et al. Mechanisms of Resistance to CDK4/6 Blockade in Advanced
Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging
Therapeutic Opportunities.</font>&#xA0;<font style="font-style: italic; font-size: 13px; font-family: Times New Roman">Clin
Cancer Res</font><font style="font-size: 13px; font-family: Times New Roman">. 2022;
28(5):821-30.</font></font><br></font></div>
<div style="margin-left: 24px; margin-right: 0px; text-indent: -24px; color: #000000; letter-spacing: normal; white-space: normal; padding-top: 6px; padding-bottom: 6px"><font style="font-style: normal; font-weight: 400; font-size: 13px; font-family: Times New Roman">
<font style="color: black; font-size: 13px; font-family: Times New Roman"><font style="font-size: 13px; font-family: Times New Roman">
11.&#xA0; Scabia V, et al. Estrogen receptor positive breast
cancers have patient specific hormone sensitivities and rely on
progesterone receptor.</font>&#xA0;<font style="font-style: italic; font-size: 13px; font-family: Times New Roman">Nat
Commun.</font>&#xA0;<font style="font-size: 13px; font-family: Times New Roman">2022;
10.1038/s41467-022-30898-0.</font></font><br></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
12.&#xA0; National Comprehensive Cancer Network. Clinical Practice
Guidelines in Oncology (NCCN Guidelines). Available
at:</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</font><font style="color: #000000; font-size: 13px">.</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</font><font style="color: #000000; font-size: 13px">Accessed
April 2024</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Adrian Kemp</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Company Secretary</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">AstraZeneca
PLC</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:
<font style="font-size: 13px">29 April 2024</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By: /s/
Adrian Kemp</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Name:
Adrian Kemp</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Title:
Company Secretary</font></div>
</td>
</tr></table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
